Genedata, a leading provider of in silico solutions for pharmaceutical R&D and related life sciences, today announced a three-year license extension with Roche for the Refiner MS module of the Genedata Expressionist® biomarker discovery system.
Refiner MS solves key requirements of large-scale proteomics and metabolomics facilities that need to efficiently process, analyze and store mass spectrometry (MS) data. As an integral part of the Expressionist biomarker discovery system, Refiner MS performs automated pre-processing of MS raw data and delivers quantified peak data ready for analysis or for storage in its relational database. All standard MS-based technologies and data formats from major instrument vendors are supported, including high and low resolution LC/GC-MSn, MALDI TOF, infusion MS, SELDI, SILAC and MRM. Refiner MS is a workflow based client-server application designed to process thousands of samples simultaneously. Its performance and scalability, coupled with superior pre-processing and unmatched visualizations, make it a unique computational solution for MS. Refiner MS is already deployed at a large number of pharmaceutical, biotechnology and agricultural research organizations to address their growing demands for high-quality biomarker identification.
“Efficient processing of raw chromatograms, accurate peak detection prior to peak identification, customizable workflows and large-scale sample processing are essential components that Refiner MS adds to the Roche biomarker discovery process,” said Dr. Hanno Langen, global head of Protein Biomarker Technologies at the Roche Molecular Medicine Laboratories. “With Refiner MS we are now able to standardize clinical proteomics applications and ensure the quality of results in this emerging field.”
“We are excited about our successful collaboration with Roche. Meeting Roche’s high processing demands has helped transform Refiner MS into an unmatched solution for proteomics research,” said Dr. Othmar Pfannes, CEO of Genedata. “Along with our recent success stories in metabolomics, Refiner MS is becoming the system of choice for all MS-based applications.”
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.
Genedata transforms data into intelligence with a portfolio of advanced software solutions for drug discovery, industrial biotechnology, and life science research. Used by a majority of the world’s top 50 pharmaceutical companies and leading research organizations, Genedata solutions make research data accessible and understandable, enabling scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Japan, Germany, and the US. www.genedata.com
Marketing & Communications
Phone: +41 61 511 8459
Phone: +1 508 881 3109
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
All product and service names mentioned are the trademarks of their respective companies.